Outcomes in Resected Melanoma Influenced by Timing of Recurrence

Published Date: 12 Aug 2024

Early recurrence after anti-PD-1/L1 likely to benefit more from anti-CTLA-4, targeted agents

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma

2.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.

3.

Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations

4.

Elder Abuse: Red Flags to Look Out For While Receiving Care.

5.

In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot